Brandes Investment Partners, LP Eagle Pharmaceuticals, Inc. Transaction History

Brandes Investment Partners, LP

$8.37 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$4.63 - $15.21 $1.8 Million - $5.92 Million	-389,283 Reduced 34.32%	745,080 $3.9 Million
Q3 2023 Nov 13, 2023	BUY	$15.21 - $22.88 $4.46 Million - $6.71 Million	293,276 Added 34.87%	1,134,363 $17.9 Million
Q2 2023 Aug 11, 2023	BUY	$17.74 - $31.87 $5.25 Million - $9.43 Million	296,037 Added 54.31%	841,087 $16.4 Million
Q1 2023 May 10, 2023	BUY	$25.06 - $34.09 $3.23 Million - $4.39 Million	128,873 Added 30.97%	545,050 $15.5 Million
Q4 2022 Feb 13, 2023	SELL	$24.98 - $39.77 $1.29 Million - $2.06 Million	-51,680 Reduced 11.05%	416,177 $12.2 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $94,187 - $167,982	3,565 Added 0.77%	467,857 $12.4 Million
Q2 2022 Aug 12, 2022	BUY	$41.26 - $51.35 $1.34 Million - $1.67 Million	32,442 Added 7.51%	464,292 $20.6 Million
Q1 2022 May 10, 2022	SELL	$44.58 - $52.6 $8.14 Million - $9.6 Million	-182,515 Reduced 29.71%	431,850 $21.4 Million
Q4 2021 Feb 11, 2022	SELL	$45.82 - $56.9 $2.69 Million - $3.34 Million	-58,711 Reduced 8.72%	614,365 $31.3 Million
Q3 2021 Nov 12, 2021	SELL	$43.79 - $55.78 $1.92 Million - $2.44 Million	-43,797 Reduced 6.11%	673,076 $37.5 Million
Q2 2021 Aug 11, 2021	BUY	$36.86 - $44.5 $8.38 Million - $10.1 Million	227,246 Added 46.41%	716,873 $30.7 Million
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $9.08 Million - $11.5 Million	225,230 Added 85.19%	489,627 $20.1 Million
Q4 2020 Feb 11, 2021	BUY	$41.72 - $51.34 $4.57 Million - $5.62 Million	109,473 Added 70.66%	264,397 $12.3 Million
Q3 2020 Nov 12, 2020	BUY	$37.02 - $51.28 $5.47 Million - $7.58 Million	147,833 Added 2084.8%	154,924 $6.58 Million
Q2 2020 Aug 12, 2020	SELL	$43.24 - $55.02 $6.21 Million - $7.9 Million	-143,510 Reduced 95.29%	7,091 $340,000
Q1 2020 May 13, 2020	BUY	$34.37 - $60.07 $5 Million - $8.73 Million	145,413 Added 2802.87%	150,601 $6.93 Million
Q4 2019 Feb 13, 2020	BUY	$54.32 - $64.31 $3,096 - $3,665	57 Added 1.11%	5,188 $312,000
Q3 2019 Nov 13, 2019	SELL	$53.25 - $59.98 $120,451 - $135,674	-2,262 Reduced 30.6%	5,131 $290,000
Q2 2019 Aug 13, 2019	SELL	$46.61 - $58.45 $679,806 - $852,493	-14,585 Reduced 66.36%	7,393 $412,000
Q1 2019 May 10, 2019	BUY	$38.66 - $51.82 $25,824 - $34,615	668 Added 3.13%	21,978 $1.11 Million
Q4 2018 Feb 11, 2019	BUY	$36.72 - $67.73 $648,181 - $1.2 Million	17,652 Added 482.56%	21,310 $858,000
Q3 2018 Nov 09, 2018	SELL	$66.65 - $83.86 $554,994 - $698,302	-8,327 Reduced 69.48%	3,658 $254,000
Q2 2018 Aug 13, 2018	SELL	$51.25 - $76.62 $678,242 - $1.01 Million	-13,234 Reduced 52.48%	11,985 $907,000
Q1 2018 May 15, 2018	BUY	$52.16 - $66.86 $1.32 Million - $1.69 Million	25,219 New	25,219 $1.33 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Brandes Investment Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Brandes Investment Partners, LP with notifications on news.

Account